Lyell Immunopharma appoints Mark Bachleda to Board, expanding size to 8

Lyell Immunopharma, Inc.

Board increased from 7 to 8 directors; Mark Bachleda, Pharm.D., M.B.A., appointed as Class I director effective June 9, 2025.
Term expires at 2028 annual meeting; compensation per non-employee director policy adjusted for 1-for-20 reverse stock split.
Standard indemnification agreement entered with Dr. Bachleda.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mark Bachleda

Director

LYEL · Lyell Immunopharma, Inc.

Effective: 2025-06-09
Filed: Jun 09, 2025 23:59 UTC

on June 9, 2025, the Board of Directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) increased the authorized size of the Board from seven directors to eight directors and, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Mark Bachleda, Pharm.D., M.B.A., to the Board as a Class I director.

Source: SEC EDGAR

accession 0001193125-25-137853

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.